

19 Dec 2021 | News

# Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast edition of Five Must-Know Things: Pfizer buys into inflammation and immunology; bispecifics and CAR-Ts in the spotlight at ASH; Lilly looks to volume-driven growth; and Novavax talks about diversity in clinical trials.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 17 December 2021, including: [Pfizer Inc.](#) buys into inflammation and immunology; bispecifics and CAR-Ts in the spotlight at ASH; [Eli Lilly and Company](#) looks to volume-driven growth; and [Novavax, Inc.](#) talks about how diversity in clinical trials.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Pfizer Buys Arena For \\$6.7bn In Bid To Diversify In Inflammation & Immunology](#)" - Scrip, 13 Dec, 2021.)

(Also see "[Multiple Myeloma Bispecifics Vie For Leadership Based On Safety, Combinability](#)" - Scrip, 15 Dec, 2021.)

(Also see "[Yescarta, Breyanzi Offer Practice-Changing Options For Second-Line LBCL](#)" - Scrip, 12 Dec, 2021.)

(Also see "[\*Lilly Looks To Volume-Driven Growth In Decade Ahead\*](#)" - Scrip, 15 Dec, 2021.)

(Also see "[\*For Novavax, Building Trust Was Key To Improving Diversity\*](#)" - Scrip, 14 Dec, 2021.)

[Click here to explore this interactive content online](#) ✎